In conclusion, we demonstrate the clinical significance of SEMA4D in human AML by showing that SEMA4D/PlexinB1 promotes the progression of AML by activating the PI3K/Akt signaling pathway. This evidence concerns the gene AKT1 and acute myeloid leukemia.